Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent versus sequential chemotherapy and aromatase inhibitors in adjuvant treatment of endocrine-responsive early breast cancer
2024-519087-41-00Phase 3Authorised
- Sponsor
- IRCCS Ospedale Policlinico San Martino
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of letrozole, exemestane and anastrozole in breast cancer (2 arms), sponsored by IRCCS Ospedale Policlinico San Martino. Primary endpoint: Disease-free survival (DFS). Planned start Feb 2025; status: authorised.
02
Drugs
letrozoleexemestaneanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519087-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519087-41-00.